Lords Mark Industries Limited
Incorporated in 1979, Kratos Energy & Infrastructure Ltd provides consultancy in various fields[1]
- Market Cap ₹ 67.0 Cr.
- Current Price ₹ 670
- High / Low ₹ 670 / 453
- Stock P/E
- Book Value ₹ 6,528
- Dividend Yield 0.00 %
- ROCE -22.0 %
- ROE -106 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.10 times its book value
- Promoter holding has increased by 31.8% over last quarter.
Cons
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Consulting Services
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 2.27 | 3.55 | 0.00 | 0.00 | |
| 2.17 | 3.44 | 0.50 | 0.93 | |
| Operating Profit | 0.10 | 0.11 | -0.50 | -0.93 |
| OPM % | 4.41% | 3.10% | ||
| 0.00 | 0.00 | 0.00 | -5.77 | |
| Interest | 0.00 | 0.00 | 0.44 | 0.02 |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.01 |
| Profit before tax | 0.10 | 0.11 | -0.95 | -6.73 |
| Tax % | 50.00% | 100.00% | 0.00% | 0.00% |
| 0.05 | 0.00 | -0.95 | -6.73 | |
| EPS in Rs | 0.50 | 0.00 | -9.50 | -67.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 55% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -106% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1.00 | 1.00 | 1.00 | 1.00 | 171.64 |
| Reserves | 1.95 | 1.94 | 3.27 | -3.46 | 481.11 |
| 0.87 | 0.08 | 1.20 | 5.53 | 279.75 | |
| 0.51 | 3.97 | 1.01 | 1.51 | 54.55 | |
| Total Liabilities | 4.33 | 6.99 | 6.48 | 4.58 | 987.05 |
| 0.02 | 0.02 | 0.06 | 0.05 | 72.32 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 27.89 |
| Investments | 0.21 | 0.21 | 0.00 | 0.00 | 18.58 |
| 4.10 | 6.76 | 6.42 | 4.53 | 868.26 | |
| Total Assets | 4.33 | 6.99 | 6.48 | 4.58 | 987.05 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.06 | 0.04 | 0.01 | -4.34 | |
| 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.00 | 0.00 | 0.00 | 4.33 | |
| Net Cash Flow | 0.06 | 0.04 | 0.01 | -0.01 |
| Free Cash Flow | 0.06 | 0.04 | 0.01 | -4.34 |
| CFO/OP | 60% | 36% | 0% | 467% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 94.87 | 4.11 | ||
| Inventory Days | 0.00 | 0.00 | ||
| Days Payable | ||||
| Cash Conversion Cycle | 94.87 | 4.11 | ||
| Working Capital Days | 85.22 | -50.38 | ||
| ROCE % | 3.22% | -22.01% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Jan 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Number of Employees Number ・Standalone data |
|
|||||||||
| Average Collection Period Days ・Standalone data |
||||||||||
| Operating Cycle Days ・Standalone data |
||||||||||
| Segment-wise Revenue - MedTech Rs. Crore ・Standalone data |
||||||||||
| Segment-wise Revenue - Paper Division Rs. Crore ・Standalone data |
||||||||||
| Segment-wise Revenue - Renewable Energy (Solar) Rs. Crore ・Standalone data |
||||||||||
| US FDA Registered Orthopaedic Products Number ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation Regarding Date Of Board Meeting - Approval Of Audited Financial Results For The Quarter /Year Ending 31St March,2026 And Recommended Dividend (If Any).
1d - Board meeting on 29 May 2026 to approve Q4/FY26 audited results and consider final dividend.
-
Outcome Of Monitoring Committee Meeting.
5 May - Monitoring committee approved share listing, trading on 5 June 2026, and allotment of 42.66 crore shares.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Launch Of AI-Powered Hemodialysis Centre
4 May - Launched world’s first AI-powered hemodialysis centre in Ahmedabad; plans 50 centers by March 2027.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Outcome Of Monitoring Committee Meeting Held On April 28, 2026
30 Apr - Monitoring Committee approved listing/trading resumption for June 5, 2026, and allotment of 42.66 crore shares.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Grant Of Manufacturing Licence For Medical Device.
24 Apr - Granted licence on Jan 14, 2026 to manufacture LordsMed HIV 1&2 Self Test for exports.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
-
Financial Year 2007
from bse
-
Financial Year 2002
from bse
Business Overview:[1]
Company is in the business of consultancy services for power projects and trading of machinery